You are here: Industry Insights > AMAG Pharmaceuticals

News List

Covis Group Completes Acquisition of AMAG Pharmaceuticals prnasia
November 17, 2020
Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.
AMAG Pharmaceuticals Appoints New Members…… firstwordpharma
April 15, 2019
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the election of two new members to its Board of ……
AMAG's confirmatory study of Makena to reduce risk of preterm birth misses main goals biospectrumasia
March 11, 2019
AMAG Pharmaceuticals said Friday that a confirmatory study of Makena (hydroxyprogesterone caproate) in patients with a history of a prior spontaneous singleton preterm delivery failed to meet its co-primary endpoints. Shares in the company, which gained a
AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals pharmafocusasia
January 21, 2019
AMAG Pharmaceuticals, Inc. announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company....
Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals pharmaceutical-technology
December 24, 2018
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.Astellas made an upfront payment of $164.6m and has agreed to...
AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals pharmafocusasia
December 14, 2018
AMAG Pharmaceuticals, Inc. today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company......
AMAG Pharmaceuticals Appoints Chief Compliance Officer americanpharmaceuticacreview
September 30, 2017
AMAG Pharmaceuticals announced the appointment of Tracy Palmer Berns as chief compliance officer effective immediately.
AMAG Pharmaceuticals signs US licence agreement for Intrarosa pharmaceutical-technology
February 17, 2017
Under the agreement, AMAG will receive the right to commercialise and develop Intrarosa in the US to treat VVA and female sexual dysfunction (FSD) and pay $50m to Endoceutics at closing.